Jin, Y., Wu, X., Guan, Y., Gu, D., Shen, Y., Xu, Z., … Chen, J. (2011). Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: A pooled analysis. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer, 20, 1815–1822.
To evaluate the therapeutic efficacy and safety of aprepitant for the treatment of chemotherapy-induced nausea and vomiting (CINV) during the first five days following highly or moderately emetogenic chemotherapy
Databases searched were MEDLINE and Embase. Abstracts were searched in the American Society of Clinical Oncology, Cochrane Library, and National Cancer Institute.
Search keywords were aprepitant, MK-869, substance P receptor antagonist, NK-1 receptor antagonist, and chemotherapy-induced nausea and vomiting.
Studies were included in the review if they
Studies were excluded if they
All patients were in active treatment.
Aprepitant is effective in the prevention of delayed CINV. Aprepitant improves the antiemetic effect of ondansetron and dexamethasone in patients receiving cisplatin-based chemotherapy.
Aprepitant is effective and safe for the prevention of CINV in the acute and delayed phases of treatment.